Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K current report with the SEC on September 11, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Court preliminary approval of derivative-action settlement in Kanner et al. v. Biggar et al.
ACADIA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Court preliminary approval of derivative-action settlement in Kanner et al. v. Biggar et al.
- ACADIA required to publish settlement notice and stipulation under the Court’s order
- Final settlement status remains subject to subsequent court approval
- Investors should review Exhibits 99.1 and 99.2 for settlement terms and potential company obligations
Item EX-99.1 · Exhibit EX-99.2
- Proposed derivative settlement requires governance reforms maintained for at least four years
- Defendants to pay $1.5 million in attorneys’ fees and expenses, subject to court approval
- No direct shareholder payout or common fund; settlement resolves claims without admissions of wrongdoing
- Settlement hearing scheduled January 13, 2027, with objections due December 23, 2026
- Approval would release related derivative claims and end associated governance litigation for current shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACADIA PHARMACEUTICALS INC 8-K filings
Get the next ACAD 8-K as it lands
Follow ACAD for push alerts, or ask the research agent what this filing means.